KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kymera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$108.07+3.29 (+3.14%)
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
97M of 83M shares
Institutional holders
275
48 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
2 buys · 271 sales
Net sold $299.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8,873,588 | 10.70% | 13G (passive) amendment | Aug 31, 2026 |
| Baker Bros. Advisors (GP) LLC | 8,676,797 | 10.90% | 13D (active) amendment | Dec 9, 2025 |
| Behzad Aghazadeh | 7,750,000 | 9.99% | 13G (passive) amendment | Sep 30, 2024 |
| Julian C. Baker | 6,666,540 | 9.50% | 13D (active) amendment | Jun 26, 2025 |
| Wellington Management Company LLP | 5,996,873 | 9.00% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC | 5,879,611 | 8.20% | 13G (passive) amendment | Sep 30, 2025 |
| T. Rowe Price Investment Management, Inc. | 5,460,257 | 6.70% | 13G (passive) | Mar 31, 2026 |
| Wellington Group Holdings LLP | 5,372,061 | 7.70% | 13G (passive) amendment | Jun 30, 2025 |
| Lampert Mark N | 5,237,151 | 6.30% | 13D (active) amendment | Jun 26, 2026 |
| Wellington Investment Advisors Holdings LLP | 4,412,933 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,803,227 | 5.40% | 13G (passive) amendment | Jun 30, 2025 |
| Abigail P. Johnson | 11,681,450 | 14.30% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KYMR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,349,256 | 14.85% | $1.42B | +649,306 | 0.06% |
| Baker Bros. Advisors LP | 8,657,242 | 10.41% | $992.73M | – | 4.97% |
| Avoro Capital Advisors LLC | 7,474,747 | 8.99% | $857.13M | – | 7.70% |
| Price T Rowe Associates Inc /Md/ | 7,112,980 | 8.55% | $815.65K | +1,052,133 | 0.08% |
| T. Rowe Price Investment Management, Inc. | 6,257,261 | 7.53% | $717.52K | +792,264 | 0.47% |
| BlackRock, Inc. | 5,538,210 | 6.66% | $635.07M | +477,334 | 0.01% |
| Bvf Inc/Il | 3,872,052 | 4.66% | $444.01M | −1,630,658 | 11.35% |
| Wellington Management Group Llp | 3,675,028 | 4.42% | $421.42M | −214,659 | 0.07% |
| Vanguard Portfolio Management LLC | 2,992,193 | 3.60% | $343.11M | +118,137 | 0.02% |
| Siren, L.L.C. | 2,935,830 | 3.53% | $336.65M | −251,000 | 6.81% |
| Vanguard Capital Management LLC | 2,932,378 | 3.53% | $336.26M | +52,054 | 0.01% |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | 3.42% | $326.53M | −1,730,467 | 37.05% |
| State Street Corp | 2,737,226 | 3.29% | $313.88M | +347,459 | 0.01% |
| Geode Capital Management, LLC | 1,816,331 | 2.18% | $208.32M | +170,981 | 0.01% |
| Capital Research Global Investors | 1,388,881 | 1.67% | $159.26M | −284,394 | 0.02% |
| Goldman Sachs Group Inc | 1,187,333 | 1.43% | $136.15M | +298,924 | 0.01% |
| UBS Group AG | 1,007,777 | 1.21% | $115.56M | −16,075 | 0.01% |
| Alliancebernstein L.P. | 981,521 | 1.18% | $81.75M | +93,486 | 0.03% |
| Driehaus Capital Management LLC | 919,233 | 1.11% | $105.41M | −124,350 | 0.61% |
| Merck & Co., Inc. | 772,165 | 0.93% | $88.54M | – | 16.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 275 | 97M | 100.0% | 48 / 97 | 83 / 26 | 8M | 7M |
| Q1 2026 | 256 | 96M | 100.0% | 43 / 96 | 73 / 38 | 16M | 4M |
| Q4 2025 | 255 | 90M | 100.0% | 68 / 99 | 63 / 15 | 14M | 5M |
| Q3 2025 | 210 | 81M | 97.5% | 40 / 81 | 54 / 38 | 8M | 6M |
| Q2 2025 | 210 | 79M | 95.0% | 64 / 69 | 52 / 26 | 10M | 4M |
| Q1 2025 | 173 | 73M | 87.7% | 23 / 64 | 57 / 29 | 6M | 4M |
| Q4 2024 | 180 | 72M | 86.3% | 33 / 60 | 60 / 28 | 7M | 4M |
| Q3 2024 | 176 | 69M | 83.2% | 37 / 54 | 65 / 16 | 13M | 7M |
| Q2 2024 | 157 | 68M | 81.2% | 25 / 58 | 50 / 30 | 4M | 5M |
| Q1 2024 | 164 | 69M | 82.7% | 42 / 59 | 44 / 13 | 13M | 5M |
| Q4 2023 | 136 | 61M | 73.9% | 33 / 37 | 52 / 18 | 7M | 3M |
| Q3 2023 | 121 | 57M | 69.0% | 12 / 49 | 36 / 20 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KYMR | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price New Horizons Fund, Inc. | 2,257,207 | 2.71% | $258.83M | 1.76% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,185,407 | 2.63% | $177.94M | 0.18% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,089,249 | 2.51% | $239.57M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,046,104 | 2.46% | $234.63M | 0.33% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,796,469 | 2.16% | $185.75M | 0.49% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 1,607,649 | 1.93% | $184.35M | 0.22% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,509,757 | 1.82% | $173.12M | 0.09% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,352,248 | 1.63% | $155.06M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,272,754 | 1.53% | $145.95M | 1.36% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 924,967 | 1.11% | $106.07M | 0.89% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 868,915 | 1.04% | $99.64M | 0.21% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 790,093 | 0.95% | $90.60M | 0.97% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 726,545 | 0.87% | $83.31M | 0.09% | Jun 30, 2026 |
| Vanguard Explorer Fund | 693,227 | 0.83% | $71.68M | 0.32% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 684,750 | 0.82% | $70.80M | 0.21% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer, Director | 666,568 | 0.80% | Jul 7, 2026 |
| Brian Adams | Chief Legal Officer | 50,254 | 0.06% | Sep 4, 2026 |
| Terence Rooney | Chief Medical Officer | 38,000 | 0.05% | Jul 27, 2026 |
| Noah Goodman | Chief Business Officer | 47,179 | 0.06% | Jul 2, 2026 |
| Bruce N. Jacobs | Chief Financial Officer | 248,083 | 0.30% | Jul 2, 2026 |
| Jeremy G. Chadwick | Chief Operating Officer | 44,618 | 0.05% | May 27, 2026 |
| Jared Gollob | Chief Medical Officer | 117,134 | 0.14% | Mar 4, 2026 |
| Ellen Chiniara | Chief Legal Officer | 82,326 | 0.10% | Mar 3, 2025 |
| Bruce Booth | Director | 2,396,426 | 2.88% | Jul 2, 2026 |
| Ii Gp Llc Bvf | Director | 2,104,075 | 2.53% | Jun 26, 2026 |
| Value Fund L. P. Biotechnology | Director | 2,104,075 | 2.53% | Jun 26, 2026 |
| Gp Holdings Llc Bvf | Director | – | – | Jun 26, 2026 |
| Inc/Il Bvf | Director | 2,195,696 | 2.64% | Jun 26, 2026 |
| I. Gp Llc Bvf | Director | 294,632 | 0.35% | Jun 26, 2026 |
| Value Fund Ii Lp Biotechnology | Director | 1,671,048 | 2.01% | Jun 26, 2026 |
| Mark N. Lampert | Director | 2,494,688 | 3.00% | Jun 26, 2026 |
| Value Trading Fund OS LP Biotechnology | Director | 2,350,503 | 2.83% | Jun 26, 2026 |
| Partners L. P/Il Bvf | Director | 1,627,928 | 1.96% | Jun 26, 2026 |
| Partners OS Ltd. BVF | Director | – | – | Jun 26, 2026 |
| Jeffrey W. Albers | Director | 5,000 | 0.01% | Jun 25, 2026 |
| Victor Sandor | Director | – | – | Jun 25, 2026 |
| John Maraganore | Director | – | – | Jun 25, 2026 |
| 667, L.P. | Director, 10% owner | 5,516,986 | 6.63% | Jun 25, 2026 |
| Elena Ridloff | Director | 0 | – | Jun 25, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 6,117,295 | 7.36% | Jun 25, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | – | – | Jun 25, 2026 |
| Felix Baker | Director, 10% owner | 7,955,916 | 9.57% | Jun 25, 2026 |
| Pamela Esposito | Director | 1,000 | 0.00% | Jun 25, 2026 |
| Julian Baker | Director, 10% owner | – | – | Jun 25, 2026 |
| Gorjan Hrustanovic | Director | – | – | Jun 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −2,137 | $117.57 | $251.25K | 50,254 |
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −3,025 | $116.81 | $353.35K | 52,391 |
| Brian Adams Chief Legal Officer | Sep 4, 2026 | Sale | −1,209 | $115.55 | $139.70K | 55,416 |
| Terence Rooney Chief Medical Officer | Jul 27, 2026 | Award | +38,000 | – | – | 38,000 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −50,000 | $119.00 | $5.95M | 666,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 7, 2026 | Option exercise | +50,000 | $2.08 | $104.00K | 716,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −3,336 | $116.56 | $388.84K | 666,568 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −24,105 | $114.96 | $2.77M | 713,954 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −44,050 | $115.69 | $5.10M | 669,904 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −6,626 | $113.98 | $755.23K | 738,059 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,883 | $112.80 | $212.40K | 744,685 |
| Nello Mainolfi Chief Executive Officer, Director | Jul 1, 2026 | Option exercise | +80,000 | $2.08 | $166.40K | 746,568 |
| Noah Goodman Chief Business Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −3,389 | $114.29 | $387.33K | 47,179 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −6,153 | $116.99 | $719.84K | 248,083 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −3,200 | $117.70 | $376.64K | 244,883 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −7,971 | $115.82 | $923.20K | 254,236 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Option exercise | +61,378 | $5.33 | $327.14K | 321,992 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,500 | $110.54 | $165.81K | 320,492 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,700 | $111.57 | $189.67K | 318,792 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −51,375 | $114.77 | $5.90M | 262,207 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −4,110 | $114.19 | $469.32K | 313,582 |
| Bruce N. Jacobs Chief Financial Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −1,100 | $112.79 | $124.07K | 317,692 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −934 | $111.20 | $103.86K | 2,384,685 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −5,549 | $105.78 | $586.97K | 2,446,375 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −14,798 | $106.63 | $1.58M | 2,431,577 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −19,419 | $107.76 | $2.09M | 2,412,158 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −130 | $111.20 | $14.46K | 462,856 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,078 | $110.67 | $119.30K | 462,986 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,104 | $109.75 | $121.16K | 464,064 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,498 | $108.28 | $162.20K | 465,168 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,698 | $107.76 | $290.74K | 466,666 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,133 | $106.63 | $227.44K | 469,364 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −770 | $105.78 | $81.45K | 471,497 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,723 | $110.67 | $854.70K | 2,385,619 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,968 | $109.75 | $874.49K | 2,393,342 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −10,848 | $108.28 | $1.17M | 2,401,310 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −3,024 | $107.76 | $325.87K | 466,077 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,318 | $106.63 | $247.17K | 469,101 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −848 | $105.78 | $89.70K | 471,419 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −19,093 | $107.76 | $2.06M | 2,412,747 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −14,613 | $106.63 | $1.56M | 2,431,840 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −5,471 | $105.78 | $578.72K | 2,446,453 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,239 | $109.75 | $135.98K | 463,150 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,688 | $108.28 | $182.78K | 464,389 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −907 | $111.20 | $100.86K | 2,385,747 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,602 | $110.67 | $841.31K | 2,386,654 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −1,199 | $110.67 | $132.69K | 461,951 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −157 | $111.20 | $17.46K | 461,794 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −7,833 | $109.75 | $859.67K | 2,394,256 |
| Bruce Booth Director | Jun 29, 2026 | Sale(10b5-1 plan) | −10,658 | $108.28 | $1.15M | 2,402,089 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,729 | $118.66 | $205.16K | 472,267 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −3,069 | $117.85 | $361.68K | 473,996 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,701 | $117.09 | $199.17K | 477,065 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −952 | $115.69 | $110.14K | 478,766 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −3,896 | $114.94 | $447.81K | 479,718 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −2,083 | $113.97 | $237.40K | 483,614 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −78 | $112.49 | $8.77K | 485,697 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,442 | $111.51 | $160.80K | 485,775 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −1,579 | $110.49 | $174.46K | 487,217 |
| Bruce Booth Director | Jun 26, 2026 | Sale(10b5-1 plan) | −4,562 | $109.79 | $500.86K | 488,796 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nello Mainolfi Officer, Director | Oct 1, 2026 | 30,000 | $3.35M | Oct 1, 2026 | Exercise of stock options |
| Adams Brian Officer | Sep 4, 2026 | 6,371 | $747.19K | Sep 4, 2026 | Shares acquired upon vesting of Restricted Stock Units awarded under the Issuer's 2020 Equity Incentive Plan. |
| Chadwick Jeremy Officer | Sep 2, 2026 | 10,879 | $1.30M | Sep 2, 2026 | Exercise of Stock Options |
| Nello Mainolfi Officer, Director | Jul 7, 2026 | 50,000 | $5.95M | Jul 7, 2026 | Exercise of stock options |
| Nello Mainolfi Officer, Director | Jul 2, 2026 | 80,000 | $9.14M | Jul 1, 2026 | Exercise of stock options |
| Goodman Noah Officer | Jul 1, 2026 | 3,389 | $388.62K | Jul 1, 2026 | Restricted Stock Units |
| N. Jacobs Bruce Officer | Jun 30, 2026 | 77,109 | $8.43M | Jun 30, 2026 | Exercise of Stock Options |
| Atlas Venture Opportunity Fund I, LP Shareholder | Jun 29, 2026 | 10,473 | $1.13M | Jun 29, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Jun 29, 2026 | 66,177 | $7.16M | Jun 29, 2026 | Private Placement |
| Atlas Venture Opportunity Fund I, LP Shareholder | Jun 26, 2026 | 57,451 | $6.69M | Jun 26, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Jun 26, 2026 | 410,427 | $47.80M | Jun 26, 2026 | Private Placement |
| Partners L. P/Il Bvf Affiliate of Director | Jun 26, 2026 | 1,630,658 | $189.91M | Jun 26, 2026 | Acquired upon the automatic conversion of private shares in connection with the Issuer's initial public offering on August 21, 2020. The private shares were acquired and fully paid for on March 11, 20 |
| Atlas Venture Opportunity Fund I, LP Shareholder | Jun 25, 2026 | 67,329 | $6.72M | Jun 25, 2026 | Private Placement |
| Atlas Venture Fund X, LP Shareholder | Jun 25, 2026 | 480,992 | $48.04M | Jun 25, 2026 | Private Placement |
| Goodman Noah Officer | Jun 25, 2026 | 5,000 | $499.35K | Jun 25, 2026 | Exercise of Stock Options |